Mereo BioPharma Group plc
MREO
$1.74
$0.042.35%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -30.17% | 23.13% | 79.43% | 8.67% | 194.79% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -17.61% | 16.92% | 82.60% | 1.80% | 35.42% |
| Operating Income | 21.62% | -16.92% | -108.50% | -1.80% | -6,450.00% |
| Income Before Tax | -19.27% | -43.97% | 26.92% | -129.69% | -599.89% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -19.27% | -43.97% | 22.65% | -129.69% | -599.89% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -19.27% | -43.97% | 22.65% | -129.69% | -599.89% |
| EBIT | 21.62% | -16.92% | -108.50% | -1.80% | -6,450.00% |
| EBITDA | 22.10% | -17.24% | -111.10% | -1.87% | -28,537.21% |
| EPS Basic | -6.16% | -28.64% | 30.11% | -104.19% | -519.42% |
| Normalized Basic EPS | -6.13% | -28.57% | 34.11% | -104.36% | -518.39% |
| EPS Diluted | -6.16% | -28.64% | 30.11% | -104.19% | -519.42% |
| Normalized Diluted EPS | -6.13% | -28.57% | 34.11% | -104.36% | -518.39% |
| Average Basic Shares Outstanding | 12.32% | 12.00% | 10.75% | 12.43% | 13.26% |
| Average Diluted Shares Outstanding | 12.32% | 12.00% | 10.75% | 12.43% | 13.26% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |